Literature DB >> 15864352

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Kerry L Donnelly1, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864352      PMCID: PMC1087172          DOI: 10.1172/JCI23621

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Temporal pattern of de novo lipogenesis in the postprandial state in healthy men.

Authors:  Maureen T Timlin; Elizabeth J Parks
Journal:  Am J Clin Nutr       Date:  2005-01       Impact factor: 7.045

3.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.

Authors:  S H Caldwell; E E Hespenheide; J A Redick; J C Iezzoni; E H Battle; B L Sheppard
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

5.  Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects.

Authors:  L C Hudgins; M K Hellerstein; C E Seidman; R A Neese; J D Tremaroli; J Hirsch
Journal:  J Lipid Res       Date:  2000-04       Impact factor: 5.922

6.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

7.  Apolipoprotein synthesis in nonalcoholic steatohepatitis.

Authors:  Michael Charlton; Raghavakaimal Sreekumar; Deborah Rasmussen; Keith Lindor; K Sreekumaran Nair
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

8.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Authors:  A J Sanyal; C Campbell-Sargent; F Mirshahi; W B Rizzo; M J Contos; R K Sterling; V A Luketic; M L Shiffman; J N Clore
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

9.  Metformin in non-alcoholic steatohepatitis.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; M Zoli; N Melchionda
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

10.  Association of nonalcoholic fatty liver disease with insulin resistance.

Authors:  G Marchesini; M Brizi; A M Morselli-Labate; G Bianchi; E Bugianesi; A J McCullough; G Forlani; N Melchionda
Journal:  Am J Med       Date:  1999-11       Impact factor: 4.965

View more
  1041 in total

1.  Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.

Authors:  Hussam Alamri; Nathan Heath Patterson; Ethan Yang; Pablo Zoroquiain; Anthoula Lazaris; Pierre Chaurand; Peter Metrakos
Journal:  Anal Bioanal Chem       Date:  2018-12-05       Impact factor: 4.142

Review 2.  The role of lipid droplets in metabolic disease in rodents and humans.

Authors:  Andrew S Greenberg; Rosalind A Coleman; Fredric B Kraemer; James L McManaman; Martin S Obin; Vishwajeet Puri; Qing-Wu Yan; Hideaki Miyoshi; Douglas G Mashek
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

Review 3.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 4.  Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen Previs; Takhar Kasumov
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

5.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; Monica L Kearney; Jacqueline M Crissey; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

6.  The effects of α-lipoic acid on liver oxidative stress and free fatty acid composition in methionine-choline deficient diet-induced NAFLD.

Authors:  Milena N Stanković; Dušan Mladenović; Milica Ninković; Ivana Ethuričić; Slađana Sobajić; Bojan Jorgačević; Silvio de Luka; Rada Jesic Vukicevic; Tatjana S Radosavljević
Journal:  J Med Food       Date:  2013-12-10       Impact factor: 2.786

Review 7.  Modulation of hepatic steatosis by dietary fatty acids.

Authors:  Alessandra Ferramosca; Vincenzo Zara
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Fasting enriches liver triacylglycerol with n-3 polyunsaturated fatty acids: implications for understanding the adipose-liver axis in serum docosahexaenoic acid regulation.

Authors:  Kristin A Marks; Phillip M Marvyn; Juan J A Henao; Ryan M Bradley; Ken D Stark; Robin E Duncan
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

10.  Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes.

Authors:  Thomas E Akie; Marcus P Cooper
Journal:  J Vis Exp       Date:  2015-08-27       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.